TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Of Bacterial Lysate In Children With Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children of both genders aged 5 to 17 years.~2. Children with grass pollen-induced allergic rhinitis recognized and treated according to current ARIA (Allergic Rhinitis and its Impact on Asthma) recommendations.~3. Positive skin prick test to grass pollen allergens or positive specific IgE (defined as ≥ class 2, ≥ 0,70 kU/l) against timothy grass pollen allergens.~4. Presentation of clinical symptoms of the allergic rhinitis (rhinorrhea, nasal congestion, nasal itching, sneezing) in at least two recent grass pollen seasons in Poland before inclusion in the study.~5. Proper use of PMBL sublingual tablets.~6. Written informed consent obtained from parents/guardians before any study related procedures are performed.~Exclusion Criteria:~1. Patient received mechanical or any other polyvalent bacterial lysate immunostimulation within the previous 12 months before visit 1.~2. Patient received oral/subcutaneous allergen-immunotherapy within the previous 3 years before the start of the study.~3. Vaccination performed within 3 months before the beginning of the study.~4. Deficiencies in cellular and humoral immunity.~5. Treatment with systemic corticosteroids within the last 6 months before the start of the study.~6. Pregnant or breastfeeding woman.~7. Other chronic conditions of the nose or nasal sinuses.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ismigen (Type: EXPERIMENTAL): Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
- Placebo (Type: PLACEBO_COMPARATOR): Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Intermittent Hypoxia and Body Weight Supported Treadmill Training for Incomplete Spinal Cord Injury Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ≥ 18 years-old from Instituto Teletón Santiago and Hospital Clínico Mutual de seguridad.~2. C5 to T12 spinal cord injury, classified as ISNCSCI grades C and D~3. Traumatic and non-traumatic, non-progressive lesions~4. Onset \> 6 months~5. Ability to ambulate with or without assistive devices~6. Ability to follow verbal or visual commands~7. Signed informed consent~Exclusion Criteria:~1. Orthopedic injuries that are unstable~2. Osteoporosis with high risk of pathological fracture~3. Cutaneous lesions and/or pressure ulcers~4. Joint contractures~5. Cardiopulmonary diseases~6. Body weight exceeding 150 Kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acute Intermittent Hypoxia Arm (Type: EXPERIMENTAL): AIH protocol: it consists of 15, 90-second hypoxic episodes (FiO2=0.09) interspersed with 15, 90-second normoxic intervals (FiO2=0.21) for a total time of 45 minutes. This protocol will be repeated every day for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks. After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
- Normoxia Arm (Type: PLACEBO_COMPARATOR): Sham protocol: it consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy of Azithromycin and Levamisole Versus of Azithromycin in in the Treatment of Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who had at least 20 papules and/or pustules,~2. Patients with nodule and/or cyst disregarding the number of papules of pustules, were included the study. There was not any age limit~Exclusion Criteria:~1. were using any type of systemic treatment for their acne at the time of visit or during the last month;~2. had any hematological, renal or hepatic disease~3. were pregnant or lactating;~4. had drug-induced acne;~5. were using alcohol, anti-convulsants or anti-coagulants.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Azithromicine plus levamisole (Type: EXPERIMENTAL): None
- Azithromicin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* at least 2 lines of previous chemotherapy~* recurrent ovarian cancer~* patient is mobile~* informed consent~Exclusion Criteria:~* ileus~* necessity of parenteral nutrition

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- intraperitoneal chemotherapy (Type: EXPERIMENTAL): Intraperitoneal chemotherapy with cisplatin at a dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% and doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution with a flow of 30 ml/min and a max upstream pressure of 200 psi.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female patients aged 40 with stable moderate to severe COPD (GOLD guidelines).~* Post-salbutamol (FEV1) \< 80% and ≥ 30% of predicted normal value and Post-salbutamol FEV1/FVC \< 70%.~* Current or ex smokers of 10 pack-years.~Exclusion Criteria:~* Patients with no history or current diagnosis of asthma.~* No evidence of an exacerbation within 6 weeks prior to the screening visit.~* No evidence of clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities.~* No contraindication to use of anticholinergic drugs such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium 400 μg bid (Type: EXPERIMENTAL): Aclidinium bromide 400 μg twice-daily by inhalation
- Tiotropium 18 μg once-daily (Type: ACTIVE_COMPARATOR): Tiotropium 18 μg once-daily by inhalation
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with thiazolidinedione (TZD) alone or in combination with metformin. TZD dose stable for at least 120 days prior to screening, and those patients on metformin must have been on a stable dose for at least 30 days prior to screening.~* HbA1c between 7.1% and 10.0%, inclusive.~* Body mass index (BMI) between 25 kg/m\^2 and 45 kg/m\^2.~Exclusion Criteria:~* Patient previously in a study using exenatide or GLP-1 analogs.~* Treated with oral anti-diabetic medications other than TZD and metformin within 3 months of screening.~* Treated with oral insulin within 3 months of screening.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): After a 2-week placebo lead-in period, exenatide will be given in an esclating dose along with the subject's current therapy regimen
- Placebo (Type: PLACEBO_COMPARATOR): After a 2-week placebo lead-in period, subjects will be given placebo (in equivalent amounts to exenatide) in addition to their current therapy regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* Subjects who have a current herpes virus infection.~* Have neonatally acquired herpes at risk of potential recurrence.~* Immunocompromised or cancer patients at risk for development of a herpes virus infection.~Exclusion criteria:~* Hypersensitivity to antiherpetic medications.~* Impaired hepatic or renal function.~* Show presence of other serious or unstable underlying disease.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Subjects in the age group of 2 to less than 6 years will be included
- Cohort 2 (Type: EXPERIMENTAL): Subjects in the age group of 1 to less than 2 years will be included
- Cohort 3 (Type: EXPERIMENTAL): Subjects in the age group of 6 months to less than 1 year will be included
- Cohort 4 (Type: EXPERIMENTAL): Subjects in the age group of 3 months to less than 6 months will be included
- Cohort 5 (Type: EXPERIMENTAL): Subjects in the age group of 1 month to less than 3 months will be included

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Modal Anesthesia Protocol in Pain Management of Patients Undergoing Posterior Lumbar Spinal Fusion Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* lumbar stenosis affecting L1-S1~* Requiring Posterior Spinal Fusion Surgery~* Age 30-85 years~Exclusion Criteria:~* younger than 30 years old or older than 85 years~* Chronic Renal Disease~* Hypersensitivity to any medication~* history of chronic opioid abuse.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- MMA Protocol Group (Type: EXPERIMENTAL): Preoperative Medications~1. Orphenadrine 100mg PO once preop~2. Gabapentin 800mg PO once preop~3. Toradol 60mg IV once preop~4. Acetaminophen 1,000mg PO once preop~Intraoperative Paraspinal Infusion~1. Bupivacaine 30cc~2. Epinephrine 1cc~3. Xylocaine-MPF Intramuscular Inj 0.5% (30cc of Saline Solution)~Postoperative Medications~1. Orphenadrine 100mg PO BID~2. Gabapentin 300mg PO Q6~3. Toradol 30mg IV Q6hrs\*~4. Methylprednisolone 125mg Q8hrs
- Control (opioids) Group (Type: ACTIVE_COMPARATOR): Postoperative Medication~1-Morphine 4mg Q4hrs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent provided for the subject by a parent or legal guardian.~* Subjects whose parents the investigator believes can and will comply with the requirements of the protocol (i.e. return for follow-up visits, record safety observations, able to converse with study personnel including by telephone).~* Age 12-59 months at Visit 1, male or female~* Receipt of one or two doses of Arepanrix (adjuvanted H1N12009 vaccine, GlaxoSmithKline (GSK)) in 2009 documented by written record or attested by a confident personal recollection (window for vaccination will be 1 October 2009 to January 31, 2010).~Exclusion Criteria:~* Systemic hypersensitivity to hens' eggs or to any other Fluviral S/F vaccine component such as thimerosal~* History of a life-threatening reaction to any influenza vaccine~* Receipt of Arepanrix after January 31st , 2010~* Receipt of non-study TIV (Trivalent Influenza Vaccine)for the 2010-2011 season~* Receipt of any live vaccine within 4 weeks or inactivated vaccine within one week of study entry or planned administration of any non-study vaccines during the study period~* Thrombocytopenia or any bleeding disorder that contraindicates IM injection or blood collection~* Receipt of blood or any blood-derived products within the past 3 months~* Chronic illness at a stage that could interfere with trial participation (stable health conditions are acceptable, such as diabetes, lung disease, heart conditions etc)~* Immune compromise as a result of a medical condition, transplantation or immunosuppressive medication, not including topical or aerosol medications~* Participation in any other research study involving a non-approved drug or medical device

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 59 Months
- Healthy Volunteers: t

Study Arms:
- Fluviral (Type: EXPERIMENTAL): 0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven ovarian cancer with evidence of recurrence or progression~* Failed first-line platinum containing therapy after 6 months of treatment discontinuation~* Documented lesion as evidenced by appropriate computerized tomography (CT), magnetic resonance imaging (MRI) scan, chest x-ray, or ultrasound.~* Previous hormonal therapy or radiotherapy must be terminated at least 3 weeks before study drug administration~* Adequate bone marrow reserve: neutrophils ≥ 1.5 x 10\^9/L and platelets ≥ 100 x 10\^9/L~Exclusion Criteria:~* Receiving concomitant cytotoxic or other antineoplastic treatment. Hormone replacement therapy is allowed, as are steroid antiemetics~* Clinical evidence of central nervous system metastases~* Active infection~* Cannot adequately be followed up for the duration of the study~* A second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)~* Use of any investigational agent in the 3 weeks prior to inclusion~* Serious concomitant systematic disorders incompatible with the study~* Received more than one previous chemotherapy regimen or had prior gemcitabine treatment~* Patients with tumor of borderline malignancy~* Patients with estimated GFR ≤ 50 mL/min

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Karnofsky performance status ≥ 60 (i.e. requires occasional assistance, but is able to care for most of their personal needs)~* For patients on medical treatment for Cushing's disease the following washout periods must be completed before screening assessments are performed~  * Inhibitors of steroidogenesis (ketoconazole, metyrapone): 1 week~ * Pituitary directed agents: Dopamine agonists (bromocriptine, cabergoline) and PPARγ agonists (rosiglitazone or pioglitazone): 4 weeks~ * Octreotide LAR, Lanreotide SR and Lanreotide autogel: 14 weeks~ * Octreotide (immediate release formulation): 1 week~Exclusion Criteria:~* Patients who are considered candidates for surgical treatment at the time of study entry~* Patients who have received pituitary irradiation within the last ten years prior to visit 1~* Patients who have had any previous pasireotide treatment~* Patients who have been treated with mitotane during the last 6 months prior to Visit 1~* Diabetic patients on antihyperglycemic medications with poor glycemic control as evidenced by HbA1c \>8%~* Patients with risk factors for torsade de pointes, i.e. patients with a baseline QTcF \>470 ms, hypokalemia, uncontrolled hypothyroidism, family history of long QT syndrome, or concomitant medications known to prolong QT interval~* Female patients who are pregnant or lactating, or are of childbearing potential (defined as all women physiologically capable of becoming pregnant) and not practicing an effective method of contraception/birth control. Sexually active males must use a condom during intercourse while taking the drug and for 2 months after the last dose of study drug and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 mg LAR dose (Type: EXPERIMENTAL): Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
- 30 mg LAR dose (Type: EXPERIMENTAL): Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Capable of giving informed consent~* Duration of peritoneal dialysis \> 3 months~* Dose of phosphate binder(s) stable over previous 2 week period~* Plasma phosphours \> 4.9 mg/dL based on most recent laboratory data within 1 month of enrollment~Exclusion Criteria:~* Pregnancy~* Known liver disease~* Active peptic ulcer disease~* Treatment with carbamazepine~* Intolerance to niacinamide or niacin~* Current medication regimen including niacin or niacinamide \> 100 mg daily~* Planned or expected surgical procedure in the next 4 months~* Patients in nursing home or extended care facilities where administration of the study drug may not be appropriately given

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- 1 (Type: EXPERIMENTAL): Niacinamide starting at 250 mg twice daily titrated up to 750 mg twice daily
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female and at least 18 years of age~* Female patients must be of either:~  * Non-childbearing potential, post-menopausal~ * Childbearing potential, provided there are negative serum and urine pregnancy test results prior to study treatment, to rule out pregnancy~Exclusion Criteria:~* Cosmetic or therapeutic procedures within 2 weeks and 2cm of the selected treatment area~* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks~* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks and 2 cm of the selected treatment area

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEP005 gel (Type: EXPERIMENTAL): PEP005 gel, 0.015% applied once daily for three consecutive days
- Vehicle gel (Type: PLACEBO_COMPARATOR): Vehicle gel applied once daily for three consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete